VOR BIOPHARMA INC (VOR) Fundamental Analysis & Valuation

NASDAQ:VOR • US9290332074

Current stock price

14.15 USD
+0.34 (+2.46%)
Last:

This VOR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. VOR Profitability Analysis

1.1 Basic Checks

  • In the past year VOR has reported negative net income.
  • VOR had a negative operating cash flow in the past year.
  • In the past 5 years VOR always reported negative net income.
  • VOR had a negative operating cash flow in each of the past 5 years.
VOR Yearly Net Income VS EBIT VS OCF VS FCFVOR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • VOR's Return On Assets of -149.96% is on the low side compared to the rest of the industry. VOR is outperformed by 84.66% of its industry peers.
Industry RankSector Rank
ROA -149.96%
ROE N/A
ROIC N/A
ROA(3y)-97.09%
ROA(5y)-70.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
VOR Yearly ROA, ROE, ROICVOR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for VOR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
VOR Yearly Profit, Operating, Gross MarginsVOR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025

4

2. VOR Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for VOR has been increased compared to 1 year ago.
  • VOR has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for VOR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VOR Yearly Shares OutstandingVOR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
VOR Yearly Total Debt VS Total AssetsVOR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -4.36, we must say that VOR is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -4.36, VOR is not doing good in the industry: 61.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -4.36
ROIC/WACCN/A
WACCN/A
VOR Yearly LT Debt VS Equity VS FCFVOR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

2.3 Liquidity

  • VOR has a Current Ratio of 18.20. This indicates that VOR is financially healthy and has no problem in meeting its short term obligations.
  • VOR has a Current ratio of 18.20. This is amongst the best in the industry. VOR outperforms 93.98% of its industry peers.
  • A Quick Ratio of 18.20 indicates that VOR has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 18.20, VOR belongs to the best of the industry, outperforming 93.98% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 18.2
Quick Ratio 18.2
VOR Yearly Current Assets VS Current LiabilitesVOR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

1

3. VOR Growth Analysis

3.1 Past

  • VOR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.09%, which is quite impressive.
EPS 1Y (TTM)22.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%393.64%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, VOR will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.03% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y83.73%
EPS Next 2Y35.5%
EPS Next 3Y21.55%
EPS Next 5Y15.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
VOR Yearly Revenue VS EstimatesVOR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
VOR Yearly EPS VS EstimatesVOR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -100 -200

1

4. VOR Valuation Analysis

4.1 Price/Earnings Ratio

  • VOR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VOR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VOR Price Earnings VS Forward Price EarningsVOR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VOR Per share dataVOR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15 -20 -25

4.3 Compensation for Growth

  • A more expensive valuation may be justified as VOR's earnings are expected to grow with 21.55% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.5%
EPS Next 3Y21.55%

0

5. VOR Dividend Analysis

5.1 Amount

  • No dividends for VOR!.
Industry RankSector Rank
Dividend Yield 0%

VOR Fundamentals: All Metrics, Ratios and Statistics

VOR BIOPHARMA INC

NASDAQ:VOR (4/27/2026, 11:18:04 AM)

14.15

+0.34 (+2.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-12
Inst Owners58.78%
Inst Owner Change0.05%
Ins Owners0.01%
Ins Owner Change-17.22%
Market Cap691.23M
Revenue(TTM)N/A
Net Income(TTM)-695.98M
Analysts84.62
Price Target38.38 (171.24%)
Short Float %12.92%
Short Ratio5.71
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)811.97%
Min EPS beat(2)-1.38%
Max EPS beat(2)1625.33%
EPS beat(4)1
Avg EPS beat(4)304.18%
Min EPS beat(4)-394.6%
Max EPS beat(4)1625.33%
EPS beat(8)3
Avg EPS beat(8)143.85%
EPS beat(12)4
Avg EPS beat(12)96.37%
EPS beat(16)6
Avg EPS beat(16)72.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.69%
PT rev (3m)3.37%
EPS NQ rev (1m)29.42%
EPS NQ rev (3m)28.55%
EPS NY rev (1m)21.75%
EPS NY rev (3m)25.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-26.49
EYN/A
EPS(NY)-4.31
Fwd EYN/A
FCF(TTM)-2.94
FCFYN/A
OCF(TTM)-2.92
OCFYN/A
SpS0
BVpS-3.36
TBVpS-3.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -149.96%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-97.09%
ROA(5y)-70.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.2
Quick Ratio 18.2
Altman-Z -4.36
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)23.23%
Cap/Depr(5y)135.22%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%393.64%
EPS Next Y83.73%
EPS Next 2Y35.5%
EPS Next 3Y21.55%
EPS Next 5Y15.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-206.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.66%
EBIT Next 3Y9.28%
EBIT Next 5YN/A
FCF growth 1Y-43.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-43.2%
OCF growth 3YN/A
OCF growth 5YN/A

VOR BIOPHARMA INC / VOR Fundamental Analysis FAQ

What is the fundamental rating for VOR stock?

ChartMill assigns a fundamental rating of 2 / 10 to VOR.


What is the valuation status for VOR stock?

ChartMill assigns a valuation rating of 1 / 10 to VOR BIOPHARMA INC (VOR). This can be considered as Overvalued.


What is the profitability of VOR stock?

VOR BIOPHARMA INC (VOR) has a profitability rating of 0 / 10.


What is the expected EPS growth for VOR BIOPHARMA INC (VOR) stock?

The Earnings per Share (EPS) of VOR BIOPHARMA INC (VOR) is expected to grow by 83.73% in the next year.